Menu

Experimental Ebola Vaccine to be Used in DRC Outbreak

As the virus spreads in Democratic Republic of Congo, the World Health Organization is preparing to immunize people as soon as this week.

May 14, 2018
Kerry Grens

Sierra Leone, 2015ISTOCK, HARRY1978The World Health Organization, the government of Democratic Republic of Congo, and Merck have agreed to use Merck’s unapproved Ebola vaccine as an outbreak of the virus expands in DRC.

“The cold chain is on standby, the stockpile is on standby, the teams have been put on standby including up to 40 people that conducted the initial ring vaccination trial in Guinea,” Peter Salama, the World Health Organization’s (WHO) deputy director-general of emergency preparedness and response, said during a United Nations briefing on Friday (May 11), according to Reuters. The Guinea field trial in 2016 found the vaccine to be 100 percent effective at preventing infection among the 6,000 people who received it.

See “Ebola Vaccine Success

So far this spring, 19 people have died of Ebola in DRC. The outbreak is in a remote part of the country, where delivering the vaccine will be a challenge because it must be kept frozen. According to STAT, the cold-chain equipment to keep the vaccine chilled was to arrive in DRC yesterday and the vaccine itself will be shipped from Geneva later this week.

Despite its isolation, the outbreak’s epicenter is just three hours by road to a city of 1 million people, and public health officials are concerned it could spread, The New York Times reports.

See “Two Ebola Cases Confirmed in Democratic Republic of Congo

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
Application of CRISPR/Cas to the Generation of Genetically Engineered Mice
With this application note from Taconic, learn about the power that the CRISPR/Cas system has to revolutionize the field of custom mouse model generation!
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
Translational Models of Obesity, Dysmetabolism, Diabetes, and Complications
This webinar, from Crown Bioscience, presents a unique continuum of translational dysmetabolic platforms that more closely mimic human disease. Learn about using next-generation rodent and spontaneously diabetic non-human primate models to accurately model human-relevant disease progression and complications related to obesity and diabetes here!
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
BiochemAR: an augmented reality app for easy visualization of virtual 3D molecular models
Have you played Pokemon Go? Then you've used Augmented Reality (AR) technology! AR technology holds substantial promise and potential for providing a low-cost, easy to use digital platform for the manipulation of virtual 3D objects, including 3D models of biological macromolecules.